Is This MedTech Giant a Buy for Dividend Investors?
Buying industry-leading companies in industries with growth potential tends to produce delightful results for dividend investors. This is because such businesses can generate revenue and earnings growth, which can fuel rising dividend payments.
The medtech juggernaut (NYSE: SYK) has been a tremendous dividend grower over the years. But is the stock still a buy for investors searching for dividend growth? Let's scrutinize Stryker's fundamentals and current valuation to decide.
Sporting a $106 billion market capitalization, Stryker is the third-biggest medical devices company in the world. This is only behind the respective $188 billion and $113 billion market values of Abbott Laboratories and Medtronic.
Source Fool.com
Stryker Corp. Aktie
296,60 €
2,88 %
Einseitige Meinung: Stryker Corp. erhält nur Buy-Einschätzungen und keine Sell-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für Stryker Corp. mit einem Kursziel von 338 € im Vergleich zum aktuellen Kurs von 296.6 €.
